BLT confirms expanded launch into the Australian market

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 5804, Dunedin 9058, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz



27 March 2019
Blis Technologies confirms expanded launch into the Australian market with
partner iNova Pharmaceuticals

Blis Technologies Limited (NZX:BLT) confirmed today that the previously announced launch
of the Company’s expanded product range into the Australian pharmacy network will take
place from 1
st
of April.
Blis CEO Brian Watson commented the launch is another important milestone in realising
the Company’s growth ambitions.
"Our products are hitting the Australian shelves with strong support from our exclusive
distribution partner in this market. iNova Pharmaceuticals has exceptional reach into the
Australian Pharmacy channel and a proven track record of establishing category leading
brands in consumer health care.”
iNova Pharmaceuticals (iNova) will be launching BLIS
®
branded products from the BLIS
K12
TM
based range: ThroatGuard
TM
, ImmuneDefence
TM
, HoneyBlis
TM
, DailyDefence
Junior
TM
, TravelProtect
TM
as well as a Difflam
®
co-branded offer Difflam 1st Signs Defence
TM
into the Australian pharmacy network. The launch will be supported through a
comprehensive consumer and trade marketing programme that coincides with the build-up
towards the busy winter season.

The BLIS product range will help solidify iNova’s leadership within the throat category in
Pharmacy by extending its offering to include a full continuum of products that can not only
manage sore throat pain but also help prevent this issue occurring in the first place. Unlike
most probiotics which work in the gut, BLIS K12 specifically targets and protects the gateway
to the body – the mouth and throat.
Mr Watson added “While our initial focus has been to finalise the launch into the Australian
market we are also exploring opportunities for the next phase of our expansion into select
new markets across Asia and Africa for which iNova is our exclusive distribution partner.”
For further information please contact:
Brian Watson
Chief Executive Officer
027 705 9133

About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production
controls enables the delivery of probiotic solutions for specific health targets including throat
health, halitosis (bad breath), immune support and teeth and gum health. BLIS products are
sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information
about Blis Technologies Ltd can be found at www.blis.co.nz.

About iNova Pharmaceuticals
iNova Pharmaceuticals (iNova) is a multinational pharmaceutical and consumer health care
company that markets and sells a wide range of market-leading products, primarily in the
areas of weight management, cough & cold, throat, skin care and natural health. iNova
operates in over 20 countries across Asia-Pacific and Africa. The iNova vision is to provide
trusted brands that improve people’s health and well-being every day. iNova is continually
seeking innovative prescription medicines and consumer health care products through
acquisition, licensing and co-marketing partnerships. iNova is ultimately owned by funds
advised and managed by Pacific Equity Partners and The Carlyle Group. More information
about iNova can be found at www.inovapharma.com.